Literature DB >> 17009972

Expression of aminopeptidase N/CD13 in human ovarian cancers.

P Surowiak1, M Drag, V Materna, S Suchocki, R Grzywa, M Spaczyński, M Dietel, J Oleksyszyn, M Zabel, H Lage.   

Abstract

Aminopeptidase N/CD13 (EC 3.4.11.2) is suggested to play a role in cancer cells invasion, and its activity can be inhibited using specific inhibitors. CD13 inhibitors evoke apoptosis of CD13-positive cancer cells. However, expression of CD13 has not been described in specimens obtained from ovarian carcinomas. Thus, in the present study, the expression of CD13 and its significance was examined in samples of ovarian cancers. The analyses were performed on sections originating from 73 tumor samples (43 from primary laparotomies [PL] and 30 from secondary cytoreductions [SCRs]). Immunohistochemical reactions were performed on paraffin sections of studied tumors, using monoclonal antibodies against CD13. The analysis demonstrated no relationships between the expression of CD13 on one hand and clinical variables and pathologic variables of the patients on the other hand. Expression of CD13 was demonstrated to be significantly more pronounced in samples obtained in PLs as compared to samples from SCRs (P < 0.001). Thus, the data indicate that a potential treatment of ovarian carcinoma with CD13 inhibitors should be performed before chemotherapy or in parallel to first-lapse chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17009972     DOI: 10.1111/j.1525-1438.2006.00657.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  18 in total

1.  Putative mesenchymal stem cells isolated from adult human ovaries.

Authors:  Martin Stimpfel; Petra Cerkovnik; Srdjan Novakovic; Ales Maver; Irma Virant-Klun
Journal:  J Assist Reprod Genet       Date:  2014-05-21       Impact factor: 3.412

2.  Enhanced expression of CD13 in vessels of inflammatory and neoplastic tissues.

Authors:  Paola Di Matteo; Gian Luigi Arrigoni; Luca Alberici; Angelo Corti; Corrado Gallo-Stampino; Catia Traversari; Claudio Doglioni; Gian-Paolo Rizzardi
Journal:  J Histochem Cytochem       Date:  2011-01       Impact factor: 2.479

3.  Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.

Authors:  Qian Liu; Hang Dong; Wei Zhao; Guozhen Zhang; Shunda Li; Qifu Xu; Yingjie Zhang
Journal:  ACS Med Chem Lett       Date:  2021-11-10       Impact factor: 4.345

4.  The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.

Authors:  Malin Wickström; Caroline Haglund; Henrik Lindman; Peter Nygren; Rolf Larsson; Joachim Gullbo
Journal:  Invest New Drugs       Date:  2007-10-06       Impact factor: 3.850

5.  Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.

Authors:  Kristina Viktorsson; Carl-Henrik Shah; Therese Juntti; Petra Hååg; Katarzyna Zielinska-Chomej; Adam Sierakowiak; Karin Holmsten; Jessica Tu; Jack Spira; Lena Kanter; Rolf Lewensohn; Anders Ullén
Journal:  Mol Oncol       Date:  2016-01-02       Impact factor: 6.603

6.  First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.

Authors:  Åke Berglund; Anders Ullén; Alla Lisyanskaya; Sergey Orlov; Hans Hagberg; Bengt Tholander; Rolf Lewensohn; Peter Nygren; Jack Spira; Johan Harmenberg; Markus Jerling; Carina Alvfors; Magnus Ringbom; Eva Nordström; Karin Söderlind; Joachim Gullbo
Journal:  Invest New Drugs       Date:  2015-11-10       Impact factor: 3.850

7.  An Automatic Platform Based on Nanostructured Microfluidic Chip for Isolating and Identification of Circulating Tumor Cells.

Authors:  Hei-Jen Jou; Li-Yun Chou; Wen-Chun Chang; Hsin-Cheng Ho; Wan-Ting Zhang; Pei-Ying Ling; Ko-Hsin Tsai; Szu-Hua Chen; Tze-Ho Chen; Pei-Hsuan Lo; Ming Chen; Heng-Tung Hsu
Journal:  Micromachines (Basel)       Date:  2021-04-21       Impact factor: 2.891

8.  CD13 is a useful tool in the differential diagnosis of meningiomas with potential biological and prognostic implications.

Authors:  Stefano Marletta; Claudio Luchini; Nicola Sperandio; Evelin Torresani; Alessandro Sorio; Ilaria Girolami; Aldo Scarpa; Albino Eccher; Claudio Ghimenton
Journal:  Virchows Arch       Date:  2022-02-25       Impact factor: 4.535

9.  Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Authors:  Lars Henning Schmidt; Caroline Brand; Janine Stucke-Ring; Christoph Schliemann; Torsten Kessler; Saliha Harrach; Michael Mohr; Dennis Görlich; Alessandro Marra; Ludger Hillejan; Carsten Müller-Tidow; Georg Lenz; Eva Wardelmann; Rainer Wiewrodt; Wolfgang E Berdel; Christian Schwöppe; Wolfgang Hartmann
Journal:  PLoS One       Date:  2017-06-12       Impact factor: 3.240

10.  Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells.

Authors:  Mikio Terauchi; Hiroaki Kajiyama; Kiyosumi Shibata; Kazuhiko Ino; Akihiro Nawa; Shigehiko Mizutani; Fumitaka Kikkawa
Journal:  BMC Cancer       Date:  2007-07-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.